

Epidemiological, diagnostic and treatment particularities in HIV/HCV co-infected patients

Dr. Cristiana Oprea

"Carol Davila" University of Medicine and Pharmacy "Victor Babes" Clinical Hospital of Infectious and Tropical Diseases, Bucharest Workshop HEPCARE EUROPE 30th March 2017


Agenda

- Epidemiology of HIV/HCV
- Diagnostic methods in HIV/HCV co-infected patients
- DAA treatment in HIV/HCV co-infected patients
- Drug drug interactions in HIV/HCV co-infected patients
- HCV treatment as prevention

Who should be tested for HCV?


- Intravenous or smoking/snorting drug users
- HIV-infected patients
- Persons with tattoos or piercing, made in unsterile conditions
- Persons born between 1950 1990 and/or who received blood transfusions before 1992
- Sexual partners of HCV-infected patients (higher risk in MSM)
- Incarcerated persons or those with history of imprisonment
- Migrants from endemic areas for HCV
- Dialyzed patients
- Persons with history of surgery or invasive procedures (especially before 1992)
- Pregnant women and newborns of HCV-infected mothers
- Persons with increased liver enzymes

Estimated number of HIV/HCV and HIV/HBV co-infected patients




Thrift A et al Nature 2017

Prevalence of HCV and HBV infection in the general population and in people who inject drugs




HIV/AIDS infection in Romania 31th December 2016 (period of time 1985 - 2016)



Compartment for Monitoring and Evaluation of HIV/AIDS in Romania - "Matei Bals" National Institute for Infectious Diseases, Romanian Ministry of Health


cART combined antiretroviral treatment

Pyramid of ages for HIV-infected patients in Romania



Compartment for Monitoring and Evaluation of HIV/AIDS in Romania - "Matei Bals" National Institute for Infectious Diseases, Romanian Ministry of Health


Dynamics of the HIV epidemic in Romania (2007 - 2016)




IDU, injection drug users; MSM, men who have sex with men

CNLAS Romania 1st December 2015 http://www.cnlas.ro/images/doc/01122015_rom.pdf


Trends of HIV transmission in Romania (2007 - 2016)




Immunologic status in newly HIV diagnosed patients in 2016



Immunologic status for intravenous drug users




HCV, HCV and HBV/HCV co-infection in HIV-positive patients in Romania (1985-2016)



Prevalence of HCV, HBV, TB and STIs in HIV-infected IDUs


Screened for	Number of patients with a positive test	%		
HBs Ag	1/100	1.00%		
HCV	82/100	82.00%		
HBs Ag + HCV	9/100	9.00%		
Syphilis	10/100	10.00%		
TBC	37/100	37.00%		

Number of IDUs among newly HIV diagnosed cases in "Victor Babes" Clinical Hospital between 2007-2015



Source: Statistics Department from "Victor Babes" Hospital Bucharest *Oprea C et al. EACS 2013, 16–19 October, Brussels

Prevalence of HCV infection in patients from Swiss cohort (SHCS)



Hahne et al BMC Inf Dis 2013

Diagnostic methods in HIV/HCV infected patients (1)

Chronic hepatitis C and screening for other types of hepatitis

- Anti HCV antibodies may be detected between 1 and 6 months after infection and may be absent in severe immunosuppressed patients (rarely)
- HCV RNA
- Test for HBsAg, Anti HBs antibodies and Anti HBc
- Test for IgG anti HAV antibodies

Diagnostic methods in HIV/HCV infected patients (2)

Evaluation of liver disease:

- Complete blood count, liver enzymes
- Staging of liver fibrosis using: liver biopsy, FibroScan, serological markers for fibrosis: (APRI, FIB4)
- Function of the liver (blood coagulation, albumin)
- Hepatic ultrasound: every 6 months for patients with cirrhosis
- Digestive endoscopy: at diagnosis and each 2 3 years for patients without esophageal varices

A HIV-infected patient with positive serology for HCV:

- NEEDS COUNSELING BOTH BEFORE AND AFTER TESTING
- NEEDS EVALUATION OF HCV VIRAL LOAD AND LIVER FIBROSIS STAGE
- IN CASE OF ADVANCED FIBROSIS, HIGH LEVEL OF LIVER ENZYMES, HIGH HCV VIRAL LOAD OR EXTRAHEPATIC MANIFESTATIONS – ANTIVIRAL TREATMENT IS INITIATED
- IN CASE OF POSITIVE SEROLOGY BUT WITH NONE OF THE ABOVE SIGNS ONLY COUNSLING


What do we need to know before DAA treatment initiation?

- HCV genotype
- HCV viral load (HCV RNA)
- Resistant mutations for HCV (excepting genotype 1b) only in particular cases/special situations
- Fibrosis stage (Fibroscan, biochemical markers- Fibromax, liver biopsy (puncture)
 - cirrhosis yes/no
 - yes decompensation stage (Child- Pugh, ascites, encephalopathy)
 - decompensated cirrhosis don't use protease inhibitors


Previous treatment with IFN or DAA – virological response (yes/no)

- Anti HCV treatment pay attention to drug drug interaction with ART!
- Renal function evaluation: Creatinine clearance
- Immunologic and virological status in HIV-infected persons (CD4+, HIV-RNA)
- Fertile women (RBV has teratogenic effects!)

All anti HCV treatments are now efficient and well tolerated



Anti HCV medication: Mechanisms of action



Regimens approved by FDA for HCV treatment

	SMV ± SOF ^[2]	LDV/SOF[3]	DCV + SOF ^[4]	OBV/PTV/ RTV ± DSV ^[5,6]	EBR/GZR ^[7]	SOF/VEL[8]
Regimen Components						
 PegIFN 	±					
• RBV	±	±	±	±	±	±
 NS5B nuc 	± SOF	SOF	SOF			SOF
NS5B non-nuc				± DSV		
 NS3/4 PI 	SMV			PTV	GZR	
• NS5A		LDV	DCV	OBV	EBR	VEL
FDA Approval by HCV Geno	type					
• GT1	1	~	~	1	~	~
• GT2						~
• GT3			~			~
• GT4	1	~		1	1	~

Therapeutic regimens for HIV/HCV co-infected patients

Genotip	Regim terapeutic	Durata tratament la	Durata tratament	Durata tratament in	
VHC		non-cirotici (sapt)	in CH compensata	CH decompensata	
1 si 4	SOF+ SMP± RBV	12 s fara RBV	12 s + RBV	Nu se recomanda	
			24 s fara RBV		
	SOF/LDP ± RBV	12 s fara RBV	12 s + RBV sau 24	s fara RBV la cirotici	
	SOF+ DCV ± RBV	12 s fara RBV	sau pre/post-transp		
			12 s + RBV sau 24 s fara RBV la ciro		
			sau pre/post-transp	lant	
	OBV/PTV/r + DSV	12 s in GT1b	Nu se recomanda		
	OBV/PTV/r + DSV + RBV	12 s in GT1a	12 s in GT1b	Nu se recomanda	
			24 s in GT 1a		
	OBV/PTV/r + RBV	12 s in GT4	24 s in GT4	Nu se recomanda	
	EBR + GZP*	12 s			
	SOF/VEL*	12 s			
2	SOF + DCV± RBV	12 s fara RBV	16-24 s fara RBV	12 s + RBV	
	SOF + RBV	12 s	16-20 s		
	SOF/VEL*	12s			
3	SOF + PEG-IFN/RBV	Nu se recomanda	12 s la cei eligibili	Nu se recomanda	
			pt IFN		
	SOF + RBV	24 s	Nu se recomanda		
	SOF + DCV± RBV	12 s fara RBV	24 s + RBV		
	SOF/ VEL*	12 s	12 s		
5	SOF/LDP	12 s	12 s		
	SOF/VEL*	12 s		6	

EASL/ AASLD guidelines 2016

HCV genotype 1b: treatment recommendations for naïve patients

Without cirrhosis – treatment duration: 12 weeks

- Sofosbuvir/Ledipasvir
- Elbasvir/Grazoprevir
- Sofosbuvir/Velpatasvir
- Ombitasvir/Paritaprevir/ritonavir/ Dasabuvir
- Sofosbuvir/Daclatasvir
- Simeprevir/ Sofosbuvir

AADLD/ IDSA guidelines 2016

Compensated cirrhosis – treatment duration: 12 weeks

- Sofosbuvir/Ledipasvir
- Elbasvir/Grazoprevir
- Sofosbuvir/Velpatasvir
- Ombitasvir/ Paritaprevir/ritonavir/ Dasabuvir

HCV genotype 3: treatment recommendations for naïve patients

Without cirrhosis – treatment duration: 12 weeks


- Sofosbuvir/Velpatasvir
- Sofosbuvir/Daclatasvir

Compensated cirrhosis – treatment duration: 12 weeks

- Sofosbuvir/Velpatasvir 12 sapt
- Sofosbuvir/Daclatasvir +/- RBV 24 sapt daca exista mutatii de rezistenta (Y 93H)


Studies regarding new therapeutic regimens in HIV/HCV co-infected patients

ASTRAL 5 – Sofosbuvir/Velpatasvir 12 s N = 106



Wyles D, EASL 2016

C- EDGE (GRAZOPREVIR/ ELBASVIR) N = 218



Rockstroh JK et al, Lancet HIV 2015

Treatment duration and monitoring in HIV/HCV co-infected patients

• Treatment duration: is similar to mono- infected patients - 12 weeks

Treatment duration shorter than 12 weeks is NOT recommended in HIV/HCV coinfected patients, black individuals and in those with IL28b CT/TT polymorphism

(AASLD/IDSA guidelines 2016)

• Treatment monitoring:

Complete blood count, liver enzymes

Renal function

HCV-RNA evaluation after 4 weeks (!) and after **12** (+/- 24) **weeks** after DAA treatment is completed

```
CD4 cell count and HIV – RNA evaluation (each 3 months)
```


Drug – drug interactions between antiretroviral treatment and Direct-Acting Antiviral drugs (DAA)

HCV drugs	ATV/r	DRV/r	LPV/r	EFV	ETR	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
BCV		Ļ	Ļ	Ļ	î	Ļ				Ť						
DCV	1			Ļ	Ļ	Ļ				Ļ						
OBV/PTV/r+DSV	1		Ť		L.	Ļ				÷ †						
SMP	t.	1	1	1	1	1				1						
SOF																
SOF/LDV				Ļ						↑						
TEL	Ļ	Ļ	Ļ	Ļ		Ļ										
SOF/VEL																
EBR/GZP								1				P = = = = = = = = = = = = = = = = = = =				•

ATV/r = atazanavir/ritonavir DRV/r = darunavir/ritonavir LPV/r = lopinavir/ritonavir RTV= ritonavir EFV= efavirenz ETR= etravirina NVP = nevirapina RPV = rilpivirina MVC= maraviroc

DTG= dolutegravir EVG/c = elvitegravir/ cobicistat RAL = raltegravir ABC = abacavir FTC= emtricitabina 3TC = lamivudine TDF = tenofovir ZDV = zidovudine

Liver metabolism of antiviral drugs



Dick T et al, Hepatology 2015

Drug – drug interactions HIV/HCV


	SMV + SOF	SOF	LDV/SOF	DCV + SOF	OMV/PTV/RTV + DSV
Atazanavir + RTV	Х	V	~	*	V
Darunavir + RTV	Х		≈	\checkmark	х
Lopinavir/RTV	Х		~		х
Tipranavir + RTV	6.40 Step				
Efavirenz	http://ww	/w.hiv	v-druginte	eraction	s.org
Rilpivirine		v	J		, s
Etravirine	8	\checkmark	\checkmark	~	8
Raltegravir	V	V	\checkmark	\checkmark	V
Elvitegravir + COBI	Х	~	~	æ	~
Dolutegravir	V	V	\checkmark	V	V
	\checkmark		\checkmark	\checkmark	*
Maraviroc					V

A A A DIDAA HAVE TE D 1 0045

Pay attention to special situations!!

- Risk of HBV reactivation at 4 8 weeks after DAA treatment initiation (29 de cases of reactivation Bersoff- Matcha SJ AASLD 2016- LB 17)
- Patients treated with regimens containing VEL or LDV and concomitant cART (based on TDF) need periodical monitoring of the renal function; this combination has to be avoided in case of creatinine clearance < 60 ml/min
- Recommendations for patients with impaired renal function (Creatinine clearance< 30 ml/min) and genotype 1b: Ombitasvir/Paritaprevir/ritonavir/Dasabuvir, for genotype 1a, 1b or 4: Elbasvir/Grazoprevir
- The risk of HCC may persist after DAA treatment (Romano A AASLD 2016) screening for hepatic carcinoma is still recommended after DAA treatment (hepatic ultrasound twice/year)
- Risk of re-infection in intravenous drug users or MSM patients (Lambers FA AIDS 2011, Ingiliz et al Journal of Hepatology 2017)

Risk of re-infection in MSM patients




Ingiliz et al Journal of Hepatology 2017)


16.8

"Treatment as prevention" in HCV study from Netherlands


Athena Cohort –DAA treatment with no restrictions HCV cascade of care



Reduced risk of HCV transmission Results




Syphilis and STD evolution



"Treatment as prevention" - Will it also work for HCV?

Dutch modelling study

Immediate initiation of DAA treatment is cost –efficient and may reduce (but not eliminate) the risk of HCV transmission among MSM



Hullegie SJ et al P 526 - CROI 2016

The role of GPs in the management of HCV-infected patient

Primary prevention methods

Counseling regarding the risk of transmission of viral hepatitis viruses (B, C, D) by iv drugs and sexual contacts

Secondary prevention methods

Links patients to centers where HCV test, disgnosis and treatment is available Gives indications about how to change the life style, diet, alcohol Immunizations Evaluation of psycho-social problems Tertiary prevention methods

Psycho-social support Education DAA treatment monitoring

Barry et al. Ir J Med Sci, 2004.

Take home messages

• In the last years a remarkable progress in diagnosis and treatment of chronic HCV was achieved.

SVR with the new antiviral regimens (DAAs) – 95%

- The response to DAAs is similar for HCV mono-infected and HIV/HCV co-infected patients
- HIV/HCV co-infected patients need drug-drug interaction evaluation
- Treatment duration shorter than 12 weeks is not recommended in HIV/HCV coinfected patients.

Take home message

- IDUs and MSM patients have a higher risk of HCV re-infection
- Even if the risk of liver disease progression is lower in patients with sustained virologic response and they have a higher quality of life, these patients still need to be monitored for hepatic carcinoma
- The rate of HCV transmission may be reduced if universal treatment will be available ("treatment as prevention" for HCV)
- The magnitude of HCV infection may be reduced by :
- Intensifying screening programmes for HCV detection (HEPCARE EUROPE)
- Active management for HCV-infected patients (including those from vulnerable groups)

Thank you!

